Antibody Therapeutics Market - Global Forecast 2025-2030

The antibody therapeutics market is undergoing rapid transformation, with advanced biologics reshaping treatment approaches across a range of diseases. Senior decision-makers require a clear view of evolving market trends, regulatory policies, and strategic innovation drivers to capitalize on new therapeutic frontiers.

Market Snapshot: Antibody Therapeutics Market Growth and Forecast

The Antibody Therapeutics Market grew from USD 256.28 billion in 2024 to USD 287.58 billion in 2025. It is expected to continue growing at a CAGR of 12.45%, reaching USD 518.32 billion by 2030. Growth is driven by technological advancements in antibody engineering, integration of digital technologies, and increased stakeholder collaboration. Dynamic shifts in research, manufacturing capabilities, and access to innovative modalities accelerate the market’s evolution and diversify therapeutic options across geographical regions.

Scope & Segmentation

• Antibody Types: Antibody fragments, antibody-drug conjugates (ADCs), bispecific antibodies, monoclonal antibodies, polyclonal antibodies
• Administration Routes: Intravenous, subcutaneous
• Source Origins: Chimeric, human, humanized
• Disease Areas: Autoimmune and inflammatory diseases, hematology, immunology, neurology, oncology, osteology, rare diseases
• Applications: Diagnostics, research, therapeutics
• End-User Dynamics: Hospitals, research institutes, specialty clinics
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies Profiled: AbbVie Inc., Adaptimmune Therapeutics PLC, Almac Group Limited, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Grifols S.A., Incyte Corporation, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., UCB S.A., Xencor Inc., Kyowa Kirin Co. Ltd.
• Technologies and Modalities: Monoclonal and bispecific antibodies, antibody-drug conjugates, antibody fragments, advanced molecular engineering, artificial intelligence for antibody design, cloud-based genomic data sharing, automated biomanufacturing, predictive modeling, real-time analytics

Key Takeaways: Market and Industry Insights

• Pipeline diversification is accelerating, with increases in collaborative research driving novel constructs for oncology, rare diseases, and chronic disorders.
• Digital technologies and artificial intelligence are reducing discovery and development timelines, supporting real-time cross-institutional data collaboration, and enabling more nuanced candidate optimization.
• Expanded subcutaneous delivery and low-immunogenicity fragments enhance patient access and treatment flexibility beyond inpatient settings.
• Strategic alliances between biotech innovators and large pharmaceutical companies foster efficient candidate development and risk-sharing, supporting larger commercial rollouts.
• Resilient supply chains, enabled by contract manufacturing and modular production, help mitigate raw material disruptions and maintain consistent clinical timelines.
• Regional segmentation allows leaders to tailor market-entry strategies, while adaptive regulatory engagement accelerates development in diverse healthcare environments.

Tariff Impact: Navigating US Tariff Policy Changes in 2025

Upcoming tariff policies in the United States will influence manufacturing costs and supply chain strategies for antibody therapeutics. Companies will need to reassess supplier networks, consider vertical integration, and diversify sourcing to address increased import duties and logistical uncertainties. Flexible procurement and inventory management will become central to protecting development schedules and cost effectiveness.

Methodology & Data Sources

This report is based on workflow-driven primary research—including in-depth executive interviews and stakeholder consultations—and thorough secondary research using peer-reviewed literature, regulatory filings, and industry event analysis. Quantitative data are triangulated with qualitative insights and validated with industry specialists to ensure robust, bias-mitigated intelligence for stakeholders.

Why This Report Matters

• Identify the most promising antibody modalities and technologies to prioritize for portfolio development and resource allocation.
• Understand the commercial and regulatory implications of global market segmentation, supporting effective regional strategy design.
• Prepare for regulatory and external policy shifts by gaining actionable intelligence on supply chain and partnership models.

Conclusion

Senior leaders will benefit from clear visibility into the antibody therapeutics ecosystem’s strategic drivers, risks, and opportunities. Drawing on rigorous research, this report helps organizations align growth strategies with the realities shaping the industry’s future.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.